Interview with Robert Dahan, President, AstraZeneca France
You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a…
Address: 1 Place Louis Renault, Rueil-Malmaison cedex 92844,France
Tel: 33 (0)1 41 29 40 00
Web: http://www.astrazeneca.fr/accueil/
AstraZeneca provides medical professionals and patients know how and drugs already widely recognized. The French subsidiary of AstraZeneca was the first European subsidiary of the group and the third in the world after the United States and Japan.
With a turnover of 1.23 billion euros in 2008, AstraZeneca is the 6th largest pharmaceutical company in France while employing 1,900 people.
In France, AstraZeneca is involved in all stages of the life of the drug research, development, production, marketing. Besides the headquarters in Rueil-Malmaison and medical networks present throughout the territory, the company has a center of Cancer Research in Reims and two industrial sites in Dunkirk and Reims.
AstraZeneca has a broad range of effective drugs and innovative, designed to combat disease in areas where medical needs are greatest.
ANESTHESIA
HEART
GASTROINTESTINAL ENTEROLOGY
INFECTIOLOGY
ONCOLOGY
RESPIRATORY
CENTRAL NERVOUS SYSTEM
You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a…
Philippe Chêne, president of Winncare, highlights the key developments of the group over the past three years – most notably its acquisition of the UK player Mangar Health. Chêne goes…
Christine Placet, CEO of French biotech Horama, discusses the objective of becoming one of the key players in the field of ophthalmic gene therapy. She explains how Horama’s unique pipeline…
Thomas Clozel, co-founder and CEO of OWKIN, elaborates on how AI can be applied to the pharmaceutical industry to revolutionize today’s drug discovery and development process. He also comments on…
André Choulika, Chairman and CEO of Cellectis, discusses how UCART will revolutionize cell therapy as a universal gene-edited solution as opposed to the current therapies on the market which uses…
Bertrand L’Huillier, president of Smith & Nephew France, highlights how the medtech firm is able to understand the objectives and needs of hospitals better with a B2B approach. He also…
Claude Le Pen, a prominent healthcare economist and consultant for IQVIA, shares his view on the state of French and European social dynamics today and outlines the key trends shaping…
François Vorms, managing director of Canon Medical Systems France, shares the story of how the company navigated its transition from Toshiba to become a well-known player in the medical imaging…
Elie Lobel, CEO of Orange Healthcare, explains how digitalization is bringing together stakeholders from across the healthcare continuum, allowing increased information exchange and connectivity. Lobel also gives insight into the…
Eric Le Roy, director general of SNITEM (Syndicat National de l’Industrie des Technologies Médicales, The French National Association of the Medical Technologies Industry) discusses the profile of French medtech today,…
Vincent Pont, president of Laboratoire Arrow, explains the company’s history, its collaboration with Aurobindo, the Indian generic pharmaceuticals group, the company’s unique positioning as a leader in the generic hospital…
Bertrand de Lavenne, general manager of Mylan France, explains how the affiliate is positioned within the group’s operations and how the Mylan strategy is to be a key actor in…
Christophe Lala, general manager of western Europe for GE Healthcare offers an overview of the current dynamics impacting the French healthcare landscape – namely a shift in structure around care…
See our Cookie Privacy Policy Here